Pharmacogenetic study to predicting clinical response of oxaliplatin in patients with advanced colorectal cancer

患者对奥沙利铂诱导的神经病变的易感性差异很大。在这项研究中，我们研究了奥沙利铂诱导的神经病变与以下多态性之间的关系：谷胱甘肽S-转移酶p（GST P1）Ile^<105>瓦尔，乙醛酸转氨酶（AGXT）Pro^<11>Leu和AGXT Ile^<340>Met。82例经组织学确诊的日本结直肠癌患者接受了至少6个周期的改良FOLFOX 6（m-FOLFOX 6）方案治疗，2/3级神经病变组中携带至少一个GST 1 ^<105>瓦尔等位基因的患者多于1级神经病变组，但差异无统计学意义（41% vs 24%，P=0.098）。2<105>/3级神经病变组和1级神经病变组中携带至少一个AGXT^ Met等位基因的患者数量相似（16% vs 13% ; P=0.725）。AGXT^<11>Leu等位基因在我们的任何患者或对照中均未发现。

Susceptibility to oxaliplatin-induced neuropathy differs greatly among patients. In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms : glutathione S-transferase p (GSTP1) Ile^<105>Val, and glyoxylate aminotransferase (AGXT) Pro^<11>Leu and AGXT Ile^<340>Met. Eighty-two Japanese patients with histologically confirmed colorectal cancer who received at least six cycles of the modified FOLFOX6 (m-FOLFOX6) regimen were enrolled.There were more patients carrying at least one GSTP1^<105>Val allele among the group with grade 2/3 neuropathy han among the group with grade 1 neuropathy although the difference was not statistically significant (41% vs 24%, P=0.098). There were similar numbers of patients carrying at least one AGXT^<105>Met allele in the grade 2/3 neuropathy and grade 1 neuropathy groups (16% vs 13% ; P=0.725). The AGXT^<11>Leu allele was not found in any of our patients or controls.